AIFF
Firefly Neuroscience, Inc.
Software - Application
Market Cap$27M
5Y Perf.-54.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AIFF vs MBRX
Revenue, margins, valuation, and 5-year total return — side by side.
MBRX
Moleculin Biotech, Inc.
Biotechnology
Market Cap$29M
5Y Perf.-97.5%
AIFF vs MBRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AIFF | MBRX |
|---|---|---|
| Industry | Software - Application | Biotechnology |
| Market Cap | $27M | $29M |
| Revenue (TTM) | $783K | $0.00 |
| Net Income (TTM) | $-21M | $-24M |
| Gross Margin | 65.9% | — |
| Operating Margin | -12.5% | — |
| Total Debt | $694K | $222K |
| Cash & Equiv. | $2M | $9M |
AIFF vs MBRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AIFF
MBRX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Firefly Neuroscienc… (AIFF) | 100 | 46.0 | -54.0% |
| Moleculin Biotech, … (MBRX) | 100 | 2.5 | -97.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AIFF vs MBRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MBRX leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Firefly Neuroscience, Inc. is the stronger pick specifically for capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
AIFF
Firefly Neuroscience, Inc.
The Income Pick
AIFF is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.48
- -54.0% 10Y total return vs MBRX's -99.7%
- Lower volatility, beta 0.48, current ratio 0.53x
Best for: income & stability and long-term compounding
MBRX
Moleculin Biotech, Inc.
The Growth Play
MBRX carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 82.0%
- -10.1% revenue growth vs AIFF's -78.3%
- 0.5% margin vs AIFF's -27.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MBRX | -10.1% revenue growth vs AIFF's -78.3% |
| Quality / Margins | MBRX | 0.5% margin vs AIFF's -27.1% |
| Stability / Safety | AIFF | Beta 0.48 vs MBRX's 1.22 |
| Dividends | MBRX | 0.4% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | MBRX | +143.1% vs AIFF's -36.1% |
| Efficiency (ROA) | MBRX | -112.5% ROA vs AIFF's -170.8% |
AIFF vs MBRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMBRXLAGGINGAIFF
AIFFFirefly Neuroscience,…
2leads
MBRXMoleculin Biotech, In…
3leads
6 Total Categories
CATEGORYLEADERvs AIFFMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MBRX1/1
Valuation MetricsMultiples, price ratios, and targets
AIFF1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MBRX3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
MBRX4/6
Risk & VolatilityBeta, volatility, and downside exposure
AIFF2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MBRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AIFF and MBRX operate at a comparable scale, with $783,000 and $0 in trailing revenue.
| Metric | AIFFFirefly Neuroscie… | MBRXMoleculin Biotech… |
|---|---|---|
| RevenueTrailing 12 months | $783,000 | $0 |
| EBITDAEarnings before interest/tax | -$10M | -$25M |
| Net IncomeAfter-tax profit | -$21M | -$24M |
| Free Cash FlowCash after capex | -$8M | -$23M |
| Gross MarginGross profit ÷ Revenue | +65.9% | — |
| Operating MarginEBIT ÷ Revenue | -12.5% | — |
| Net MarginNet income ÷ Revenue | -27.1% | — |
| FCF MarginFCF ÷ Revenue | -10.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +67.2% | +134.5% |
MBRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
AIFF leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | AIFFFirefly Neuroscie… | MBRXMoleculin Biotech… |
|---|---|---|
| Market CapShares × price | $27M | $29M |
| Enterprise ValueMkt cap + debt − cash | $26M | $21M |
| Trailing P/EPrice ÷ TTM EPS | -1.21x | -0.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 254.01x | — |
| Price / BookPrice ÷ Book value/share | — | 1.96x |
| Price / FCFMarket cap ÷ FCF | — | — |
AIFF leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
MBRX leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
AIFF delivers a -2.2% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-3 for MBRX.
| Metric | AIFFFirefly Neuroscie… | MBRXMoleculin Biotech… |
|---|---|---|
| ROE (TTM)Return on equity | -2.2% | -3.2% |
| ROA (TTM)Return on assets | -170.8% | -112.5% |
| ROICReturn on invested capital | — | -4.4% |
| ROCEReturn on capital employed | — | -187.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.01x |
| Net DebtTotal debt minus cash | -$1M | -$9M |
| Cash & Equiv.Liquid assets | $2M | $9M |
| Total DebtShort + long-term debt | $694,000 | $222,000 |
| Interest CoverageEBIT ÷ Interest expense | -105.82x | — |
MBRX leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
MBRX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MBRX five years ago would be worth $486 today (with dividends reinvested), compared to $256 for AIFF. Over the past 12 months, MBRX leads with a +143.1% total return vs AIFF's -36.1%. The 3-year compound annual growth rate (CAGR) favors MBRX at -40.8% vs AIFF's -49.5% — a key indicator of consistent wealth creation.
| Metric | AIFFFirefly Neuroscie… | MBRXMoleculin Biotech… |
|---|---|---|
| YTD ReturnYear-to-date | +116.9% | -31.5% |
| 1-Year ReturnPast 12 months | -36.1% | +143.1% |
| 3-Year ReturnCumulative with dividends | -87.1% | -79.2% |
| 5-Year ReturnCumulative with dividends | -97.4% | -95.1% |
| 10-Year ReturnCumulative with dividends | -54.0% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -49.5% | -40.8% |
MBRX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
AIFF leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AIFF is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than MBRX's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AIFF currently trades 51.2% from its 52-week high vs MBRX's 31.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AIFFFirefly Neuroscie… | MBRXMoleculin Biotech… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.48x | 1.22x |
| 52-Week HighHighest price in past year | $3.77 | $7.98 |
| 52-Week LowLowest price in past year | $0.62 | $0.25 |
| % of 52W HighCurrent price vs 52-week peak | +51.2% | +31.1% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 49.2 |
| Avg Volume (50D)Average daily shares traded | 12.5M | 113K |
AIFF leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
MBRX is the only dividend payer here at 0.35% yield — a key consideration for income-focused portfolios.
| Metric | AIFFFirefly Neuroscie… | MBRXMoleculin Biotech… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 4 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $0.01 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MBRX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AIFF leads in 2 (Valuation Metrics, Risk & Volatility).
Best OverallMoleculin Biotech, Inc. (MBRX)Leads 3 of 6 categories
Loading custom metrics...
AIFF vs MBRX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AIFF or MBRX a better buy right now?
Analysts rate Moleculin Biotech, Inc.
(MBRX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AIFF or MBRX?
Over the past 5 years, Moleculin Biotech, Inc.
(MBRX) delivered a total return of -95. 1%, compared to -97. 4% for Firefly Neuroscience, Inc. (AIFF). Over 10 years, the gap is even starker: AIFF returned -54. 0% versus MBRX's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AIFF or MBRX?
By beta (market sensitivity over 5 years), Firefly Neuroscience, Inc.
(AIFF) is the lower-risk stock at 0. 48β versus Moleculin Biotech, Inc. 's 1. 22β — meaning MBRX is approximately 153% more volatile than AIFF relative to the S&P 500.
04Which is growing faster — AIFF or MBRX?
On earnings-per-share growth, the picture is similar: Moleculin Biotech, Inc.
grew EPS 82. 0% year-over-year, compared to -384. 8% for Firefly Neuroscience, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AIFF or MBRX?
Moleculin Biotech, Inc.
(MBRX) is the more profitable company, earning 0. 0% net margin versus -96. 9% for Firefly Neuroscience, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBRX leads at 0. 0% versus -85. 0% for AIFF. At the gross margin level — before operating expenses — AIFF leads at 38. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AIFF or MBRX?
In this comparison, MBRX (0.
4% yield) pays a dividend. AIFF does not pay a meaningful dividend and should not be held primarily for income.
07Is AIFF or MBRX better for a retirement portfolio?
For long-horizon retirement investors, Firefly Neuroscience, Inc.
(AIFF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). Both have compounded well over 10 years (AIFF: -54. 0%, MBRX: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AIFF and MBRX?
These companies operate in different sectors (AIFF (Technology) and MBRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.